Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 65.5%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 5,761 shares, a decline of 65.5% from the June 30th total of 16,698 shares. Based on an average daily volume of 17,142 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the shares of the company are sold short.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Finally, Rodman & Renshaw assumed coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $34.67.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC boosted its position in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in Bolt Biotherapeutics in the 3rd quarter valued at $85,000. Susquehanna International Group LLP purchased a new stake in Bolt Biotherapeutics in the 3rd quarter worth $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Bolt Biotherapeutics in the 4th quarter worth $112,000. Finally, T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at about $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT traded up $0.10 during mid-day trading on Monday, reaching $3.93. The company’s stock had a trading volume of 200 shares, compared to its average volume of 25,796. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. Bolt Biotherapeutics has a 52 week low of $3.75 and a 52 week high of $7.20. The stock has a fifty day moving average of $4.39 and a two-hundred day moving average of $4.82. The firm has a market capitalization of $7.55 million, a PE ratio of -0.24 and a beta of 1.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million. As a group, sell-side analysts anticipate that Bolt Biotherapeutics will post -11.1 EPS for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.